GlassScriptPhysician profile
Geeta E George
NPI 1548344500
$9,252.65
in general payments reported to CMS, 2019-2025
40 companies · $872 in 2025
The $872 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,307 · 2020: $1,095 · 2021: $1,121 · 2022: $1,781 · 2023: $1,944 · 2024: $1,132 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,749 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,748.71 |
| Education | $199.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,227.33 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Janssen Biotech, INC. | $1,141.77 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Novartis Pharmaceuticals Corporation | $1,083.65 | 2019-2025 | |
| Pfizer INC. | $759.43 | 2019-2024 | |
| Seagen INC. | $758.42 | 2019-2023 | Tukysa, Adcetris |
| E.R. Squibb & Sons, L.L.C. | $717.69 | 2019-2025 | Opdivo, Opdualag |
| Abbvie INC. | $369.82 | 2021-2025 | |
| Incyte Corporation | $363.73 | 2020-2024 | Jakafi |
| Taiho Oncology, INC. | $344.98 | 2019-2025 | |
| Amgen INC. | $328.56 | 2019-2023 | Kyprolis, Xgeva, Nplate |
| Celgene Corporation | $319.69 | 2019-2024 | Reblozyl, Pomalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.49 | 2019-2021 | |
| Genzyme Corporation | $209.01 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $161.39 | 2019-2023 | Keytruda |
| Pharmacyclics LLC, An Abbvie Company | $130.58 | 2022-2023 | Imbruvica, Epkinly |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geeta George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.